Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + pemetrexed + salazosulfapyridine
- Development stage
- Unknown
- Lead developer
- Kyushu University Hospital
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of cisplatin, pemetrexed, and salazosulfapyridine (SASP). This treatment targets cancer stem cells in advanced non-squamous non-small-cell lung cancer. Salazosulfapyridine inhibits xCT, which is stabilized by CD44v (a marker of cancer stem cells in solid tumors). By inhibiting xCT, SASP suppresses the proliferation of CD44v-positive cancer cells by reducing their ability to synthesize the antioxidant glutathione.
02
Targets
SLC7A11 (Cystine-Glutamate Antiporter)
Beyond the preview
Go deeper on cisplatin + pemetrexed + salazosulfapyridine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + pemetrexed + salazosulfapyridine.